We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Deficit of Neurotrophins in Experimental Diabetes – Correction with a Proline-Containing Dipeptide.
- Authors
Ostrovskaya, R. U.; Antipova, T. A.; Nikolaev, S. V.; Kruglov, S. V.; Ozerova, I. V.; Gudasheva, T. A.; Seredenin, S. B.
- Abstract
Experiments on Wistar rats using a model of type 2 diabetes induced by streptozotocin (STZ) at a dose of 40 mg/kg addressed the effects of the proline-containing dipeptide noopept (the ethyl ester of N-phenylacetyl-L-prolylglycine) on nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) contents. Untreated diabetic rats showed 59% and 33% decreases in NGF content in the pancreas and liver, respectively, while BDNF contents decreased by 30% and 40% in the pancreas and liver, respectively, as compared with controls. Noopept given to diabetic rats at a dose of 0.5 mg/kg for 14 days increased the NGF content in the pancreas by 48% compared with untreated diabetic rats and produced a 19% increase in the NGF content in the liver as compared with the control group. Noopept given to diabetic rats normalized BDNF content in the pancreas but had no effect on the decreased level in the liver. The data obtained here identify one of the mechanisms of the antidiabetic action of noopept described in our previous reports.
- Subjects
BRAIN-derived neurotrophic factor; NEUROTROPHINS; LABORATORY rats; TYPE 2 diabetes; ANIMAL models of diabetes
- Publication
Neuroscience & Behavioral Physiology, 2019, Vol 49, Issue 7, p809
- ISSN
0097-0549
- Publication type
Article
- DOI
10.1007/s11055-019-00806-z